J Clin Oncol: Breast cancer patients with PALB2 embryo mutations can also benefit from PARPi treatment

PARP inhibitor (PARPi) Olaparib has been approved for the treatment of HER2-negative metastasis breast cancer (MBC) with BRCA1/2 embryoline (germline, g) mutations.
whether Olapali can be used in MPC patients carrying BRCA1/2 system (somatic, s) mutations or other HR-related gene g/s mutations other than BRCA1/2 is unclear.
study is an Extended Phase II Olapali study designed to assess the efficacy of Olapa in patients with the above-mentioned MPC.
recruit MVC patients who carry HR-related gene germ line mutations (queue 1) other than BRCA1/2, or THOSE-related gene (including BRCA1/2) system mutations (queue 2).
requires that patients have not been treated with PARPi in the past, non-platinum resusable diseases or past chemotherapy after progressing no more than twice.
Olapali 300 mg orthopaedia (2/day) until the disease progresses.
end points are objective mitigation rates (ORRs), and secondary endpoints include clinical benefit rates and progression-free survival (PFS).
recruited a total of 54 patients.
76% of patients were ER-positive and HER2-negative.
87% of patients carry PALB2, sBRCA1/2, ATM or CHEK2 mutations.
in queue 1, ORR is 33%, and in queue 2, ORR bit is 31%.
patients with only gPALB2 and sBRCA1/2 mutations were relieved (ORR was 82% and 50%, respectively).
13.3 months for patients with gPALB2 and 6.3 months for patients with sBRCA1/2 mutations.
patients with only ATM or CHEK2 mutations did not see remission.
PARP inhibition can effectively treat MPC patients with gPALB2 or SBRCA/2 mutations, greatly expanding the population of breast cancer patients who may benefit from PARPi therapy.
the results emphasize the value of molecular properties in MPC treatment decisions.